This trial will look at how an experimental drug, BMT, affects Type II diabetes when combined with other treatments. After 6 months, patients will have a biopsy to see if it worked.
- Kidney Disease
2 Primary · 3 Secondary · Reporting Duration: >50% from baseline, and to a level < 1000 mg/gm, at six months
1 Treatment Group
1 of 1
45 Total Participants · 1 Treatment Group
Primary Treatment: Subcutaneous Bremelanotide · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 80 · All Participants · 19 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this clinical trial actively recruiting participants?
"This clinical trial is currently recruiting participants, as indicated in its listing on clinicaltrials.gov. Initially posted on December 29th 2022 and last updated January 23rd 2023, the study seeks suitable candidates to enroll." - Anonymous Online Contributor
Is the eligibility criteria of this medical examination limited to those over twenty years old?
"As indicated by this trial's eligibility criteria, all participants must be aged between 18 and 80 years old." - Anonymous Online Contributor
Has the FDA approved Subcutaneous Bremelanotide for public use?
"Subcutaneous Bremelanotide's safety is evaluated as a 2, since there are some data points to back its security but none that can vouch for its efficacy." - Anonymous Online Contributor
How many centers are involved in the management of this experiment?
"At this time, 6 sites across the country are enlisting patients for the study. Potential enrollees can select from Decatur, Lawrenceville and Winston-Salem plus an additional six locations to minimize travel needs." - Anonymous Online Contributor
How many individuals have agreed to participate in this experiment?
"In order to successfully launch this clinical trial, 45 qualified patients must participate. These recruits can sign up at either the Decatur or Lawrenceville branches of Georgia Nephrology Research Institute." - Anonymous Online Contributor
Who meets the criteria to join this research endeavor?
"This study requires 45 individuals aged 18 to 80 that are diagnosed with kidney disease, Type II diabetes mellitus (HgbA1c ≤ 12%), BMI ≤45 kg/m^2., Stage I-III diabetic nephropathy confirmed by biopsy within the last 5 years, on a stable dose of oral diabetic agents or insulin injections for 3+ months prior to randomization, and on a stabile maximum tolerated dose of ACE or ARB as primary antihypertensive therapy. The target blood pressure must be less than 140/90 and additional medications used should have neutral effects on urinary proteinuria. Subjects taking mineralocort" - Anonymous Online Contributor